Managed Care Research in Action
Contact Hours: 1.5 | Activity Type: Knowledge-based | ACPE UAN: 0233-0000-18-072-L04-P
In the United States, a significant hurdle to the realization of value inherent in a single-dose therapy is the retention of the subscriber in his or her health plan. Today, the research and development pipeline for one-dose, high-value therapies, such as gene therapy or other innovative and regenerative therapies, is robust. But payers and manufacturers need a reasonable expectation for the length of time a patient taking the therapy may be covered by the health plan in order to realize the value of the intervention.
This session will delve into how expectations for subscriber retention can be used in the assessment of value of a one-dose, high-value therapy. The presentation will also present findings from a recent study that quantifies the longer expected retention of certain subscribers. Population-specific retention studies provide an improved expectation of the long-term value proposition of these therapies.
At the completion of this activity, participants should be able to: